7. Revolution Medicines (NASDAQ:RVMD)
Druckenmiller’s Stake: $30,717,000
Revolution Medicines (NASDAQ:RVMD) is a biotech company developing targeted cancer drugs.
Revolution Medicines (NASDAQ:RVMD) recently reported a Phase 3 win for its lead drug daraxonrasib. The results showed the candidate drug cut the risk of death by about 60% and more than doubled survival in patients with advanced pancreatic cancer compared to chemotherapy.
Additional Phase 3 programs include adjuvant PDAC settings after surgery and perioperative therapy, as well as expansion into non-small cell lung cancer (NSCLC), widening the total opportunity beyond pancreatic cancer alone.
Revolution Medicines (NASDAQ:RVMD) is also developing zoldonrasib, a selective RAS G12D inhibitor, with plans for multiple Phase 3 combinations. This creates a second growth engine targeting a high-frequency mutation in pancreatic and lung cancers.
Some also believe Revolution Medicines (NASDAQ:RVMD) could become an acquisition target for large pharma looking to deepen their oncology pipelines.
Aristotle Growth Equity Fund stated the following regarding Revolution Medicines, Inc. (NASDAQ:RVMD) in its fourth quarter 2025 investor letter:
“Revolution Medicines, Inc. (NASDAQ:RVMD) is a company focused on developing new treatments for cancer, specifically for patients whose cancers are driven by changes in RAS proteins. Their research and development is centered on creating drugs called RAS(ON) inhibitors, which aim to block the growth signals from these proteins. The company’s main drugs—Daraxonrasib, Elironrasib, and Zoldonrasib—are already being tested in clinical trials. Revolution Medicines is working on bringing a new drug, RMC-5127, into trials soon. In addition, the company is developing more targeted treatments for other types of RAS mutations.
We see Revolution as presenting a compelling investment case driven by the robust clinical performance of its lead candidate, Daraxonrasib (RMD-6236), currently in phase 3 trials for advanced non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). The drug has demonstrated impressive efficacy in hard-to-treat cancers, with high objective response and disease control rates, significantly outperforming existing standard treatments. Daraxonrasib’s U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation and inclusion in the FDA Commissioner’s National Priority Review Voucher program highlight its promise and potential for accelerated approval. With ongoing expansion into earlier lines of therapy and multiple combination studies in solid tumors, as well as a pipeline of additional agents in development, Revolution is well positioned for future growth and value creation in the oncology space. As a clinical-stage biotechnology company, valuation can be challenging given no commercial products. Sell-side analysts have projected that Daraxonrasib’s PDAC-only revenue could reach several billion dollars by the mid-2030s. This would result in a current value that is just over one times potential peak revenue, which is lower than the multiple typically seen in historical biotech merger & acquisition transactions.”
